Dabigatran in ‘real-world’ clinical practice for stroke prevention in patients with non-valvular atrial fibrillation

Tatjana S. Potpara

doi:10.1160/TH15-10-0825

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2015; 114(06): 1093-1098
DOI: 10.1160/TH15-10-0825

Invited Editorial Focus

Schattauer GmbH

Dabigatran in ‘real-world’ clinical practice for stroke prevention in patients with non-valvular atrial fibrillation

Tatjana S. Potpara

¹School of Medicine, Belgrade University, Belgrade, Serbia

²Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia

References
1 Chan NC, Paikin JS, Hirsh J. et al. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost 2014; 111: 798-807.
2 Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 111: 783-788.
3 Husted S, de Caterina R, Andreotti F. et al. Nonvitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Hae-most 2014; 111: 781-782.
4 Husted S, Lip GYH. Response to Ansell et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel”. (Thromb Hae-most 2014; 112: 841) Thromb Haemost 2014; 112: 842.
5 Ansell J, Crowther M, Burnett A. et al. Comment on: Editorial by Husted et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel”. (Thromb Haemost 2014; 111: 781–782). Thromb Haemost 2014; 112: 841.
6 Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb Haemost 2014; 111: 808-816.
7 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
8 Huisman MV, Lip GY, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
9 Vaughan Sarrazin MS, Jones M, Mazur A. et al. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014; 127: 1179-1185.
10 Larsen TB, Gorst-Rasmussen A, Rasmussen LH. et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650-656.e5.
11 Graham DJ, Reichman ME, Wernecke M. et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-164.
12 Hernandez I, Baik SH, Pinera A. et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015; 175: 18-24.
13 Lauffenburger JC, Farley JF, Gehi AK. et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015; 04: e001798.
14 Abraham NS, Singh S, Alexander GC. et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015; 350: h1857.
15 Meytal A-T- Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost. 2016 115. Epub ahead of print on September 10, 2015.
16 Seeger JD, Bykov K, Bartels DB. et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
17 Villines TC, Schnee J, Fraeman K. et al. A comparison of the safety enf effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290-1298.
18 Hijazi Z, Hohnloser SH, Oldgren J. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomised Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129: 961-970.
19 Lip GY, Clemens A, Noack H. et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014; 111: 933-942.
20 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomised evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
21 Larsen TB, Rasmussen LH, Skjoth F. et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-2273.
22 Desai J, Kolb JM, Weitz JI. et al. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost 2013; 110: 205-212.
23 Sharma M, Cornelius VR, Patel JP. et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 2015; 132: 194-204.
24 Ho CW, Ho MH, Chan PH. et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015; 46: 23-30.
25 Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: An Asian perspective. Thromb Haemost 2014; 111: 789-797.